Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters
Clinical and Molecular Hepatology · 2025
DOI: 10.3350/cmh.2024.0724 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, 2025. Verfasst von Lung-Yi Mak und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Queen Mary Hospital, The University of Hong Kong. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, RNA, Viral, Antiviral Agents, Hepatitis B virus. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Alexion Pharmaceuticals, Boehringer Ingelheim, Pfizer.
Abstract (Originalsprache)
Backgrounds/Aims: Plasma pregenomic hepatitis B virus RNA (pgRNA) is a novel biomarker in chronic hepatitis B infection (CHB). We aimed to describe the longitudinal profile of pgRNA and factors influencing its levels in CHB patients on nucleoside analogue (NUC).
Methods
Serial plasma samples from 1,354 CHB patients started on first-line NUC were evaluated. Time of NUC initiation was taken as baseline (year 0), followed by 1-year, 3-year and 5-year of NUC therapy. pgRNA was measured by Research Use Only RealTime HBV RNA v2.0 (0.2 mL) (Abbott Diagnostics) with lower limit of detection of 0.8 log U/mL (~20 copies/mL).
Results
Among 1,354 subjects (median age at baseline 49.8 [interquartile range, IQR 40.2–57.3]) years, 65.2% male, 16.1% hepatitis B e antigen (HBeAg)-positive, 28.6% cirrhotic), baseline median HBV RNA was 3.68 (IQR 2.42–5.19) log U/mL. Upon NUC therapy, median pgRNA levels were 2.45 (IQR 1.82–3.62), 2.23 (IQR 1.67–3.05) and 2.14 (IQR 1.48–2.86) log U/mL at 1, 3 and 5 years, respectively, with the corresponding log U/mL reductions of 0.82, 1.20 and 1.54. Undetectable/ unquantifiable pgRNA was achieved in 13.5%, 15.9% and 20.1% of patients at 1, 3 and 5 years, respectively. Older age, male sex, HBeAg-negativity and high PAGE-B score were associated with lower pgRNA.
Conclusions
Plasma pgRNA declines are modest under NUC therapy, with only 16.3% achieving RNA undetectability after 5 years of first-line NUC indicating cccDNA silencing has not been achieved in the majority of patients. Clinical characteristics should be taken into consideration when interpreting the plasma pgRNA level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Queen Mary Hospital, The University of Hong Kong.
- State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong.
- Abbott Laboratories, Abbott Diagnostics Division, Abbott Park, IL, USA.
Förderung
- Alexion Pharmaceuticals
- Boehringer Ingelheim
- Pfizer
- Ribo Life Science
- Gilead Sciences
- AbbVie
- Aligos Therapeutics
- AiCuris
Zitieren
APA
Mak, L. Y., Anderson, M., Stec, M., Chung, M. S., Wong, D. K., Hui, R. W., Seto, W. K., Cloherty, G., & Yuen, M. F. (2025). Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0724
Vancouver
Mak LY, Anderson M, Stec M, Chung MS, Wong DK, Hui RW, et al. Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters. Clinical and Molecular Hepatology. 2025. doi:10.3350/cmh.2024.0724
BibTeX
@article{Mak2025,
author = {Mak, Lung-Yi and Anderson, Mark and Stec, Michael and Chung, Matthew Shing-Hin and Wong, Danny Ka-Ho and Hui, Rex Wan-Hin and Seto, Wai-Kay and Cloherty, Gavin and Yuen, Man-Fung},
title = {Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters},
journal = {Clinical and Molecular Hepatology},
year = {2025},
doi = {10.3350/cmh.2024.0724}
}
EUVIMED